Compare PRCT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCT | AGIO |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2021 | 2013 |
| Metric | PRCT | AGIO |
|---|---|---|
| Price | $25.85 | $27.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $35.44 | ★ $37.63 |
| AVG Volume (30 Days) | ★ 2.1M | 664.7K |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $308,054,000.00 | $43,011,000.00 |
| Revenue This Year | $32.85 | $75.68 |
| Revenue Next Year | $24.66 | $167.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.22 | N/A |
| 52 Week Low | $19.35 | $22.24 |
| 52 Week High | $64.89 | $46.00 |
| Indicator | PRCT | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 46.39 |
| Support Level | $19.35 | $26.48 |
| Resistance Level | $29.24 | $29.49 |
| Average True Range (ATR) | 1.94 | 1.06 |
| MACD | 0.24 | -0.06 |
| Stochastic Oscillator | 56.22 | 29.67 |
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.